Cellectar Biosciences (CLRB)
(Delayed Data from NSDQ)
$2.12 USD
+0.03 (1.44%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $2.11 -0.01 (-0.47%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.12 USD
+0.03 (1.44%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $2.11 -0.01 (-0.47%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum F VGM
Zacks News
Broad Portfolio to Aid Patterson Companies' (PDCO) Q1 Earnings
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal first-quarter results are likely to reflect an improvement in both the Dental and Animal Health segments on the back of comprehensive product offerings.
Reasons to Retain Cardinal Health (CAH) in Your Portfolio Now
by Zacks Equity Research
Cardinal Health (CAH) gains from a solid pharmaceutical segment and a diversified product portfolio. However, regulatory setbacks are a concern.
Here's Why You Should Retain Accuray (ARAY) Stock for Now
by Zacks Equity Research
Accuray's (ARAY) solid product demand raises optimism about the stock.
Is Cellectar Biosciences (CLRB) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Cellectar Biosciences, Inc. (CLRB) and InMode (INMD) have performed compared to their sector so far this year.
Is CanFite Biopharma Ltd (CANF) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how CanFite Biopharma Ltd (CANF) and Cellectar Biosciences, Inc. (CLRB) have performed compared to their sector so far this year.
Zacks.com featured highlights include: RentACenter, U.S. Physical Therapy, Cellectar Biosciences, Toro and Zymeworks
by Zacks Equity Research
RentACenter, U.S. Physical Therapy, Cellectar Biosciences, Toro and Zymeworks are highlighted in this Screen of the Week article.
Ride on Rising P/E Investing With These 5 Top-Ranked Stocks
by Sanghamitra Saha
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
Baxter (BAX) Inks Sterile Manufacturing Agreement With Novavax
by Zacks Equity Research
Baxter's (BAX) BioPharma Solutions business inks deal to advance commercial-scale production and increase access for the COVID-19 vaccine in the U.K. and European markets.
5 Stocks to Invest in as Dollar Gets Its Mojo Back
by Tirthankar Chakraborty
The dollar has not only strengthened in recent times but it seems there is even more room for growth. So, let's find out which stocks stand to benefit from dollar's comeback.
Play Rising P/E Investing With These Top 5 Stocks
by Sanghamitra Saha
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.
Biocept (BIOC) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Biocept (BIOC) is expected to have suffered in Q2 from reduced oncology practices and postponement of patient appointments.
What Bargain Hunting? Tap 5 Stocks With Rising P/E
by Sanghamitra Saha
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.
Company News for May 27, 2020
by Zacks Equity Research
Companies In The News Are: EVFM, BNFT, SRNE, CLRB